The value of external beam radiation in node positive prostate cancer: A multivariate analysis

Urologic Oncology

Volumn 6, Issue 6, 2001, Pages 255-260

  Morris, A D ^a   Zietman, A L ^a   Althausen, A F ^a   Heney, N M ^a   Kaufman, D S ^a   Shipley, W U ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

External beam radiation; Node positive prostate cancer; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035165799     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(01)00122-3     Document Type: Article

References (12)

1. The challenge of treating node-positive prostate cancer
2. Time to second prostate specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease
3. Prognostic factors in carcinoma of the prostate: Analysis of RTOG study 75-06
4. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation
5. Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma
6. Extended-field radiation therapy for prostate carcinoma with para-aortic lymph node metastasis
7. Is long-term survival possible with external beam radiation for Stage D1 adenocarcinoma of the prostate
8. Combined hormonal and radiation therapy for lymph node-positive prostate cancer
9. Management of stage D1 adenocarcinoma of the prostate: The Johns Hopkins experience 1974-1987
10. Androgen suppression plus radiation vs. radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial RTOG 85-31)